Praxis Precision Medicines Announces Positive Results of EEG Analysis of PRAX-628 Phase 1 Study
07 août 2023 07h00 HE
|
Praxis Precision Medicines, Inc.
Composite qEEG measure showed change from placebo after first dose of 5 mg Effect in the composite qEEG measured through 10-day treatment period Ongoing PRAX-628 Phase 2 Photo-Paroxysmal...
Praxis Precision Medicines to Participate at the 2023 Wedbush PacGrow Healthcare Conference
03 août 2023 16h12 HE
|
Praxis Precision Medicines, Inc.
BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines Announces Closing of Financing and Reiterates Corporate Priorities
22 juin 2023 07h00 HE
|
Praxis Precision Medicines, Inc.
Strong demand for financing including full exercise of overallotment option with net proceeds of $63.3 million Cash runway extended into Q1 2025 Phase 2 Photoparoxsymal Response (PPR) study to...
Praxis Precision Medicines, Inc. Announces Pricing of $59.1 Million Public Offering
15 juin 2023 23h58 HE
|
Praxis Precision Medicines, Inc.
BOSTON, June 15, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
15 juin 2023 16h01 HE
|
Praxis Precision Medicines, Inc.
BOSTON, June 15, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for...
Praxis Precision Medicines Announces Plans to Begin Ulixacaltamide Phase 3 in Essential Tremor by Year End After Completing End of Phase 2 Meeting with FDA
09 juin 2023 07h00 HE
|
Praxis Precision Medicines, Inc.
Phase 3 program to include one parallel group study and one randomized withdrawal study mADL11 as primary endpoint Single 60 mg/day dose to be tested BOSTON, June 09, 2023 ...
Praxis Precision Medicines to Present at the 2023 Jefferies Healthcare Conference
02 juin 2023 09h00 HE
|
Praxis Precision Medicines, Inc.
BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2023 Financial Results
11 mai 2023 07h30 HE
|
Praxis Precision Medicines, Inc.
Ulixacaltamide essential tremor End-of-Phase 2 meeting with FDA scheduled for June 2023 PRAX-628 Phase 1 study results support preclinical profile indicating potential for best-in-class-efficacy for...
Praxis Precision Medicines Announces Positive Topline Results from PRAX-628 Phase 1 Study Enabling Best-in-Class Profile
11 mai 2023 06h55 HE
|
Praxis Precision Medicines, Inc.
PRAX-628 demonstrated a favorable safety and tolerability profile in healthy volunteers at concentrations more than 15-fold the MES EC50; PRAX-628 predicted therapeutic range at least 3-fold wider...
Praxis Precision Medicines to Present at the American Academy of Neurology 2023 Annual Meeting
19 avr. 2023 08h00 HE
|
Praxis Precision Medicines, Inc.
BOSTON, April 19, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...